Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Queensland Health
Argus Health

Generated: November 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,849,704

« Back to Dashboard

Summary for Patent: 5,849,704

Title: Pharmaceutical formulation
Abstract:A pharmaceutical preparation comprising a growth hormone and histidine or a derivative of histidine as additive or buffering substance shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved preparation at ambient temperature. Crystallization of growth hormone in the presence of histidine or a derivative thereof gives rise to a higher yield of crystals having a higher purity than known methods.
Inventor(s): S.o slashed.rensen; Hans Holmegaard (Virum, DK), Skriver; Lars (Ved.ae butted.k, DK), Hoelgaard; Annie Rassing (Holte, DK)
Assignee: Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:08/458,386
Patent Claim Types:
see list of patent claims
Composition; Compound; Formulation; Use;

No matches for this query

Foreign Priority and PCT Information for Patent: 5,849,704

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Denmark2046/91Dec 20, 1991
Denmark1364/92Nov 10, 1992

International Patent Family for Patent: 5,849,704

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office1197222► Subscribe
European Patent Office0618807► SubscribeSPC008/2003Ireland► Subscribe
Germany69233704► Subscribe
Denmark136492► Subscribe
Denmark204691► Subscribe
Denmark0618807► Subscribe
Germany69232847► Subscribe
Germany10399015► Subscribe
Czech Republic283361► Subscribe
Czech Republic9401507► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Queensland Health
US Army
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus